Programs

Clinical Trials

Firmonertinib

ArriVent is studying firmonertinib (previously furmonertinib) globally in patients with NSCLC with EGFR mutations or HER2 exon 20 insertion mutations. To learn more about these clinical studies, please select from below or visit clinicaltrials.gov.

FURTHER (FURMO-002)

Study of Firmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR including PACC Mutations (NCT05364073)

Learn more at clinicaltrials.gov/study/NCT05364073

FURVENT (FURMO-004)

First-line Study to Compare Firmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (NCT05607550)

Learn more at furventexon20.com

SHP2 Combination Trial

Study of Furmonertinib in combination with ICP-189, a SHP2 (SHP2i), in collaboration with Beijing InnoCare Pharma Tech Co., Ltd., in classical EGFRm Non-Small Cell Lung Cancer Patients

For more information about firmonertinib clinical studies:

800-583-7566 FURMO@arrivent.com arriventclinicalstudies.com